FindTrial
Sign In

Clinical study on the effect of sugammadex on postoperative recovery of TAVR patients

Clinical study on the effect of sugammadex on postoperative recovery of TAVR patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300069196
Enrollment
Unknown
Registered
2023-03-09
Start date
2023-03-15
Completion date
Unknown
Last updated
2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Transcatheter aortic valve replacement

Interventions

Bridion groups:Bridion
Neostigmine groups:Neostigmine

Sponsors

Guangdong Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: (1) Transcatheter aortic valve replacement for patients with severe aortic valve disease in accordance with surgical indications; (2) ASA grade ?-?, NYHA standard grade ?-? cardiac function; (3) BMI:18-28 kg/m2 (4) Patients and their family members agreed and signed the informed consent voluntarily.

Exclusion criteria

Exclusion criteria: (1) Chronic arrhythmia (including sinus bradycardia, atrioventricular block, sick sinus syndrome, etc.); (2) Patients who need to keep the endotracheal tube back to the ward after the operation; (3) neuromuscular junction diseases such as myasthenia gravis; (4) Known allergic to the observed drug.

Design outcomes

Primary

MeasureTime frame
pulmonary complications;—

Secondary

MeasureTime frame
Hemodynamic index;TOF value;PQRS score;—

Countries

China

Contacts

Public ContactHaiyan Wang

Guangdong Hospital of Traditional Chinese Medicine

wanghy006@163.com13631493942

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026